(18)F-Labelled PSMA-1007 shows similarity in structure, biodistribution and tumour uptake to the theragnostic compound PSMA-617

Eur J Nucl Med Mol Imaging. 2016 Sep;43(10):1929-30. doi: 10.1007/s00259-016-3447-9. Epub 2016 Jun 25.

Authors

Frederik L Giesel¹, Jens Cardinale², Martin Schäfer², Oliver Neels², Martina Benešová², Walter Mier¹, Uwe Haberkorn¹, Klaus Kopka², Clemens Kratochwil³

Affiliations

¹ Department for Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany.
² Division of Radiopharmaceutical Chemistry, German Cancer Research Center (DKFZ), Heidelberg, Germany.
³ Department for Nuclear Medicine, University Hospital Heidelberg, INF 400, 69120, Heidelberg, Germany. clemens.kratochwil@med.uni-heidelberg.de.

No abstract available

Publication types

Case Reports

MeSH terms

Dipeptides / pharmacokinetics*
Dipeptides / therapeutic use*
Fluorine Radioisotopes / therapeutic use
Heterocyclic Compounds, 1-Ring / pharmacokinetics*
Heterocyclic Compounds, 1-Ring / therapeutic use*
Humans
Male
Organ Specificity
Prostate-Specific Antigen
Prostatic Neoplasms, Castration-Resistant / diagnostic imaging
Prostatic Neoplasms, Castration-Resistant / metabolism*
Prostatic Neoplasms, Castration-Resistant / radiotherapy*
Radiopharmaceuticals / therapeutic use
Theranostic Nanomedicine / methods*
Tissue Distribution
Treatment Outcome

Substances

Dipeptides
Fluorine Radioisotopes
Heterocyclic Compounds, 1-Ring
PSMA-617
Radiopharmaceuticals
Prostate-Specific Antigen